APYX — Apyx Medical Corporation

Apyx Medical Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $12.9 million, up 12% from $11.5 million in Q3 2024.
• Surgical Aesthetics Revenue: Increased 19% to $11.1 million, driven by the AYON Body Contouring System launch and a 30% rise in U.S. sales.
• OEM Revenue: Declined 18% to $1.8 million, attributed to reduced sales volumes to existing customers.
• Gross Profit: Increased to $8.3 million, with a gross margin of 64.4%, up from 60.5% year-over-year.
• Operating Expenses: Decreased to $9.1 million from $10.6 million, reflecting cost-cutting measures.
• Net Loss: $2 million, or $0.05 per share, improved from a loss of $4.7 million, or $0.14 per share, in Q3 2024.
• Adjusted EBITDA Loss: Decreased 96% to $0.1 million.
• Cash Position: $25.1 million as of September 30, 2025, down from $31.7 million at year-end 2024.

2. Strategic Updates and Business Highlights

• Rebranding: The Advanced Energy segment is now called Surgical Aesthetics to better align with the company's focus on innovative surgical products.
• AYON Launch: The AYON Body Contouring System was successfully launched, receiving positive market feedback and generating preorders.
• Market Positioning: Apyx is focusing on the growing demand for body contouring solutions, particularly due to the rise of GLP-1 medications, which have increased the patient population experiencing skin laxity.
• KOL Engagement: The company hosted a successful event featuring prominent surgeons discussing AYON's capabilities, enhancing market visibility.

3. Forward Guidance and Outlook

• Updated Revenue Guidance for 2025: Expected total revenue between $50.5 million and $52.5 million, up from previous guidance of $50 million to $52 million.
• Surgical Aesthetics Segment Revenue: Projected between $43 million and $45 million, an increase from prior guidance.
• OEM Revenue Guidance: Expected to be approximately $7.5 million, down from previous guidance of $8 million.
• Gross Margin Expectation: Approximately 61% for the year, with total operating expenses not exceeding $40 million.

4. Bad News, Challenges, or Points of Concern

• OEM Revenue Decline: The decrease in OEM sales is a concern as it reflects reduced demand from existing customers.
• Cash Burn: Although cash burn has decreased, the reduction in cash reserves from $31.7 million to $25.1 million raises questions about long-term sustainability if revenue growth does not continue.
• Market Risks: The company is monitoring potential impacts from tariffs and trade policies, which could affect costs and profitability.

5. Notable Q&A Insights

• Sales Classification: AYON sales are classified differently, affecting generator sales metrics; existing customers may not need to purchase new generators if they upgrade.
• Gross Margin Expectations: Management refrained from providing specific gross margin guidance but indicated that the Surgical Aesthetics segment typically has the highest margins.
• Consumables Growth: Future growth in consumables is expected primarily from new customers rather than existing users upgrading.
• Market Dynamics: The management highlighted the ongoing disruption in the market due to GLP-1 drugs, suggesting a favorable environment for Apyx's technologies.
• International Expansion: While focused on the U.S. market for now, there are plans for international rollout in the future, particularly in Europe and Latin America.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session during Apyx Medical's Q3 2025 earnings call.